1. Sodobno vodenje trajne astmeMitja Košnik, Stanislav Šuškovič, Matjaž Fležar, Katarina Osolnik, Mihaela Zidarn, Sabina Škrgat, Saša Kadivec, 2006, pregledni znanstveni članek Povzetek: Astmo ima vsaj 5% ljudi. Bolnike duši, ker se zaradi astmatskega vnetja zožijodihalne poti. Ukrepi, ki zmanjšajo astmatsko vnetje, izboljšajo astmo. Vnetje zmanjšujemo z odstranjevanjem alergenov in dražljivcev ter predvsem z uporabo protivnetnih zdravil. Raziskave urejenosti astme po vsem svetu pokažejo, da v vsakdanjem življenju le malo bolnikov doseže tako dobro stanje urejenosti bolezni, kakršno je možno doseči v kliničnih raziskavah. Trenutno veljavne svetovne smernice za obravnavo astme imajo pomanjkljivost, da se osrediščajo v glavnem na predpisovanje zdravil. Dejstvo pa je, da na urejenostbolezni lahko vplivamo predvsem z zdravstveno vzgojo in večanjem zavzetosti bolnikov za zdravljenje.
Objavljeno v DiRROS: 28.01.2026; Ogledov: 529; Prenosov: 0 |
2. Cytokine profiles of bronchoalveolar lavage in patients with interstitial lung diseases and non-allergic asthmaDana Greif Lenarčič, Urška Bidovec, Pia Kristanc, Peter Kopač, Mateja Marc-Malovrh, Izidor Kern, Katarina Osolnik, 2025, izvirni znanstveni članek Povzetek: Diagnosing and prognosing immune-mediated airway diseases, like hypersensitivity pneumonitis (HP) and sarcoidosis, is complicated due to their overlapping symptoms and the lack of definitive biomarkers. Hence, we wanted to compare bronchoalveolar lavage (BAL) cytokine and chemokine profiles from 92 patients with different immune-mediated and inflammatory airway diseases, namely, HP, sarcoidosis, non-allergic asthma, amiodarone lung, and EGPA. We also compared pulmonary function parameters, BAL’s cellularity, and lymphocyte immunophenotypes. We found significant differences across all measured lung functions (VC, VC%, FEV1, FEV1%, and Tiff%) and in the number of macrophages, lymphocytes, neutrophils, and eosinophils. Furthermore, we showed significant differences in CD4, CD8, and CD4/8 across all included ILDs and OLDs; however, no significant differences were found in CD3, CD19, NK, or NKT. We identified nine biomarkers (IL-1β, IL-6, IL-8, IL-13, VEGF, angiogenin, C4a, RANTES, and MCP-1) that significantly differ in the BAL of patients with HP and sarcoidosis and showed that RANTES and IL-6 are associated with fibrotic outcome. We have demonstrated that interstitial and obstructive lung diseases differ in cytokine and cellular lung imprint, which may, in the future, enable the determination of the disease subtype and thus the identification of targets for the treatment of individuals or subgroups within diseases.
Ključne besede: hypersensitivity pneumonitis, sarcoidosis, non-allergic asthma, amiodarone lung, EGPA, cytokines, bronchoalveolar lavage, chemokines, complement anaphylatoxins, angiogenesis-related factors
Objavljeno v DiRROS: 05.08.2025; Ogledov: 1022; Prenosov: 597
 Celotno besedilo (1,19 MB)
Gradivo ima več datotek! Več... |
3. Utility of telomerase gene mutation testing in patients with idiopathic pulmonary fibrosis in routine practiceJulij Šelb, Katarina Osolnik, Izidor Kern, Peter Korošec, Matija Rijavec, 2022, izvirni znanstveni članek Povzetek: Recent studies have suggested that causative variants in telomerase complex genes (TCGs) are present in around 10% of individuals with idiopathic pulmonary fibrosis (IPF) regardless of family history of the disease. However, the studies used a case-control rare variant enrichment study design which is not directly translatable to routine practice. To validate the prevalence results and to establish the individual level, routine clinical practice, and utility of those results we performed next generation sequencing of TCGs on a cohort of well-characterized consecutive individuals with IPF (diagnosis established according to ATS/ERS/JRS/ALAT guidelines). Of 27 IPF patients, three had a family history of idiopathic interstitial pneumonia (familial IPF) and 24 did not (sporadic IPF). Pathogenic/likely-pathogenic variants (according to American College of Medical Genetics criteria) in TCG were found in three individuals (11.1%) of the whole cohort; specifically, they were present in 2 out of 24 (8.3%) of the sporadic and in 1 out of 3 (33.3%) of the patients with familial IPF. Our results, which were established on an individual-patient level study design and in routine clinical practice (as opposed to the case-control study design), are roughly in line with the around 10% prevalence of causative TCG variants in patients with IPF.
Ključne besede: telomerase, idiopathic pulmonary fibrosis, genetic variation, telomerase complex
Objavljeno v DiRROS: 07.02.2022; Ogledov: 2636; Prenosov: 953
Celotno besedilo (236,11 KB) |
4. Mnenje za spremljanje bolnikov po preboleli covidni pljučniciMatjaž Turel, Natalija Edelbaher, Matjaž Fležar, Matevž Harlander, Peter Kecelj, Izidor Kern, Majda Kočar, Peter Kopač, Mitja Košnik, Robert Marčun, Igor Požek, Mirjana Rajer, Irena Šarc, Jurij Šorli, Dušanka Vidovič, Katarina Osolnik, 2021, izvirni znanstveni članek Povzetek: Pljučnica je najpogostejši vzrok za težji potek okužbe z virusom SARS-CoV-2 in s hospitalizacijo. Potek covidne pljučnice je lahko različen; infiltrati, vidni na rentgenski sliki, se lahko resorbirajo spontano, včasih pa je potrebno zdravljenje s sistem-skimi glukokortikoidi. Ob odpustu iz bolnišnice zdravljenje običajno še ni končano, zato je Združenje pulmologov Slovenije v želji po enotnem obravnavanju bolnikov s covidno pljučnico izdelalo mnenje za obravnavo in sledenje bolnikov po od-pustu iz bolnišnice. Zavedamo se, da ob novi bolezni ne gre za dokončno priporočilo, saj bodo nova spoznanja o covidni pljučnici zanesljivo zahtevala obnavljanje priporočil.
Ključne besede: covid-19, mnenja, pljučnica, pulmologija, sistemski glukokortikoidi, covidna pljučnica
Objavljeno v DiRROS: 15.12.2021; Ogledov: 2735; Prenosov: 789
 Povezava na datoteko |
5. Prizadetost pljuč in srca po obsevanju ter kemoterapiji Hodgkinove bolezniLorna Zadravec-Zaletel, Katarina Osolnik, Berta Jereb, 2013, drugi znanstveni članki Povzetek: Akutne in kronične okvare pljuč po zdravljenju raka v otroštvu so po sodobnem zdravljenju redke in običajno brez kliničnih znakov ter simptomov. Pri bolnici, ki je bila v otroštvu zdravljena zaradi Hodgkinovega limfoma z obsevanjem vratu, supraklavikularnih bezgavk in mediastinuma ter s kemoterapijo, so kvarne posledice verjetna kombinacija neugodnih učinkov tega zdravljenja na srce in pljuča. Pri naši bolnici je glede na potek in napredovanje pljučne prizadetosti v ospredju vaskularna prizadetost - pljučna vaskulopatija, ki je bila s histološkim pregledom bioptata pljučnega tkiva tudi potrjena. Pri opisu želimo opozoriti na kroničen ter progredienten potek bolezni, ki terja zahtevno obravnavo specialistov in 22 let po zdravljenju povzroča težko invalidnost.
Ključne besede: Hodginova bolezen, otroci, posledice, pljuča, bolezni dihal
Objavljeno v DiRROS: 31.08.2018; Ogledov: 4902; Prenosov: 1323
Celotno besedilo (314,18 KB) |
